Quick Answer
Trevi Therapeutics, Inc. reported Research And Development Expense of $33.48 million for the year ending 2025.
- Trevi Therapeutics, Inc. showed a decrease of -15.0% in Research And Development Expense from 2024 to 2025.
- This data is from Trevi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $2.36 million | Q2 2018: $3.44 million | Q3 2018: $3.75 million | Q1 2019: $3.34 million | Q2 2019: $5.53 million | Q3 2019: $5.65 million | Q1 2020: $6.02 million | Q2 2020: $4.92 million | Q3 2020: $4.83 million | Q1 2021: $5.59 million | Q2 2021: $6.50 million | Q3 2021: $4.72 million | Q1 2022: $4.65 million | Q2 2022: $5.10 million | Q3 2022: $5.77 million | Q1 2023: $5.00 million | Q2 2023: $5.84 million | Q3 2023: $6.32 million | Q1 2024: $8.80 million | Q2 2024: $10.02 million | Q3 2024: $11.22 million | Q1 2025: $7.81 million | Q2 2025: $9.39 million | Q3 2025: $10.09 million.
- Over the full 8 years of available data (2018 to 2025), Trevi Therapeutics, Inc.'s Research And Development Expense has grown by 137.9%.
- Historical annual values: Fiscal year 2025: $33.48 million | Fiscal year 2024: $39.38 million | Fiscal year 2023: $23.68 million | Fiscal year 2022: $19.83 million | Fiscal year 2021: $22.98 million | Fiscal year 2020: $22.33 million | Fiscal year 2019: $19.34 million | Fiscal year 2018: $14.07 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: